Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Reserpine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20Linked to original sources

Depletion and repletion of cortical tissue and dialysate 5-HT after reserpine.

Reserpine (5 mg/kg s.c.) was given to rats kept under a reversed light-dark cycle and 5-hydroxytryptamine (5-HT) and 5-hydroxyindole acetic acid (5-HIAA) determined in frontal cortex tissue and dialysate at various times after drug treatment. The decline and return of spontaneous locomotor activity was also measured. Tissue 5-HT was depleted to 16% of control values 24 hr after drug administration and had recovered to 61% of control after 21 days. Locomotion was profoundly reduced by 7 hr after reserpine but had returned to normal at 4 days. Dialysate 5-HT, both basal and its rise on potassium (K+) stimulation, was reduced at 1, 7 and 21 days after reserpine but the K+ stimulated increases (as % of control) did not rise above % tissue repletion, thus providing evidence against increased mobilization of the transmitter from the partially repleted vesicular stores. However, at 1 day after reserpine, basal dialysate 5-HT was proportionately less reduced than tissue 5-HT suggesting that release from a reserpine insensitive (extravesicular) pool was more effective than from the vesicular pool. At this time, the K(+)-stimulated rise of dialysate 5-HT was proportionately more reduced than tissue 5-HT. By 21 days, values converged so that % changes of the 3 compartments were the same suggesting that at this time both basal and K+ stimulated dialysate 5-HT was essentially all derived from the vesicular pool.

Animals↗

Effect of combined reserpine and ECS on electroshock seizure thresholds in mice.

Recent evidence has suggested that electroshock seizure threshold is correlated with levels of brain biogenic amines. Reserpine, a drug that depletes serotonin and norepinephrine, has been shown to decrease seizure thresholds. ECS treatment has been shown to increase amine levels as well as seizure thresholds. Combined reserpine and ECS have been shown to produce an intermediate level of serotonin and norepinephrine, but seizure threshold data for this group is absent. It was the purpose of this study to examine the seizure thresholds for combined treatment and compare them with groups treated with reserpine alone, ECS alone, and a placebo control group. The results suggest that, if only maximal seizures are considered, the seizure threshold is lowest for the reserpine and highest for the ECS alone or control groups, with the combined treatment group falling intermediate. If both minimal and maximal seizures are considered, the reserpine and combined treatment groups do not differ from one another, but do show a lower threshold as compared to ECS or control groups.

Animals↗

Phencyclidine-induced wet-dog shakes observed in rats after withdrawal from reserpine treatment.

This study was designed to assess the involvement of serotonergic neurons in phencyclidine (PCP)-induced wet-dog shakes in rats after termination of reserpine treatment. Administration of L-5-hydroxytryptophan (7.5-12.5 mg/kg) to rats 30 min following pretreatment with pargyline induced wet-dog shakes which included head shake and whole body shake. p-Chloroamphetamine (PCA) (5 mg/kg) alone also produced wet-dog shakes in the vehicle-pretreated rats, but PCP (2.5-7.5 mg/kg) and tryptophan (100 mg/kg) alone did not. The number of wet-dog shakes significantly increased after the injection of PCA (2.5 and 5 mg/kg) in the reserpine-pretreated rats, in which the 5-hydroxyindoleacetic acid/serotonin (5-HT) ratio was significantly higher and postsynaptic 5-HT receptors were also in a state of supersensitivity, compared to that of the vehicle-pretreated rats. PCP (2.5-7.5 mg/kg) also produced wet-dog shakes in a dose-dependent fashion in rats after pretreatment with reserpine. Furthermore, PCP-induced wet-dog shakes were potentiated by imipramine, a 5-HT-uptake blocker, and prevented by mianserin, a 5-HT receptor-blocker. Tryptophan (100 mg/kg) alone produced wet-dog shakes in the reserpine-pretreated rats and it was enhanced in combination with imipramine. These results may indicate that the PCP-induced wet-dog shakes after reserpine withdrawal are due to an increased release of 5-HT from the functional pool and supersensitivity of postsynaptic 5-HT receptors.

Animals↗

The effects of acute cocaine administration on the DOI-induced head-twitch response in reserpinized mice.

Previously it was shown that acute cocaine administration dose dependently reduces the 5-HT2-receptor-mediated DOI [(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]-induced head-twitch response (HTR) in mice via indirect stimulation of the inhibitory adrenergic alpha 2- and serotonergic 5-HT1A receptors. In addition, the inhibitory capacity of cocaine was enhanced fourfold in mice with 5-HT2-receptor supersensitivity induced by a single injection of DOI 48 h prior to experimentation. The aim of the present investigation was to determine the inhibitory capacity of cocaine in reserpinized mice. A single injection of reserpine 48 h prior to DOI administration caused supersensitivity in the DOI-induced HTR. Two reserpine injections did not further enhance this supersensitivity effect. Once reserpinized 5-HT2-receptor supersensitive animals were less responsive to the inhibitory effects of cocaine on the DOI-induced behavior than were the mice, as reported previously, that were made supersensitive by DOI pretreatment. The inhibitory capacity of cocaine was further attenuated when mice were reserpinized twice prior to determination of its effects on the DOI-induced behavior. Taken together with previously published data, the present investigation lends further support for the importance of endogenous levels of 5-HT and norepinephrine on the ability of cocaine to attenuate the DOI-induced HTR.

Amphetamines↗

Differential effects of chronic reserpine exposure on Ca2+ sequestering mechanisms in rat submandibular gland vesicles.

To determine the effects of exposure to reserpine on subcellular Ca2+ transporting systems, active Ca2+ uptake was measured with and without ruthenium red in submandibular gland vesicles obtained from rats after chronic treatment with reserpine. The properties of ruthenium red-sensitive Ca2+ uptake were similar to those measured in submandibular gland vesicles from untreated rats: it was abolished by the dye, was relatively low at 1 microM Ca2+ but increased markedly at millimolar Ca2+ levels and was positively and significantly correlated with the mitochondrial membrane marker, cytochrome-C oxidase activity, in membrane subfractions obtained by differential centrifugation (r = 0.67, p = 0.0005, n = 29). On the other hand, ruthenium red-insensitive Ca2+ uptake, though stimulated at submicromolar Ca2+ concentrations, was reduced by a mean of 54% compared to preparations from untreated animals and particulate RNA content was 18% of that found in control preparations. Moreover, the distributions of ruthenium red-insensitive Ca2+ uptake and particulate RNA (which are closely correlated in vesicles from untreated rats) were not significantly related when measured in vesicles of submandibular glands from reserpine treated rats. Other membrane markers and overall membrane protein content were not significantly altered after chronic reserpine exposure. We conclude that reserpine treatment has little effect on mitochondrial Ca2+ uptake capacity but abolishes or drastically reduces the high affinity Ca2+-sequestering activity which, in submandibular gland vesicles from untreated rats, is apparently associated with the endoplasmic reticulum.

Animals↗

Repeated administration of desmethylimipramine blocks the reserpine-induced increase in tyrosine hydroxylase mRNA in locus coeruleus neurons of the rat.

The levels of tyrosine hydroxylase and galanin mRNA were measured by in situ hybridization histochemistry in the rat locus coeruleus after repeated (21 days) administration of desmethylimipramine (10 mg/kg/day), of reserpine (0.25 mg/kg/day), of coadministered desmethylimipramine and reserpine, or of vehicle. Reserpine administration resulted in increased levels of both tyrosine hydroxylase and galanin mRNAs in locus coeruleus neurons as compared to vehicle-treated controls. Administration of desmethylimipramine alone failed to alter either the tyrosine hydroxylase or galanin mRNA. However, coadministration of desmethylimipramine with reserpine blocked the elevation in tyrosine hydroxylase mRNA induced by reserpine alone.

Animals↗

Effect of reserpine and colchicine on neuropeptide mRNA levels in the rat hypothalamic paraventricular nucleus.

Using in situ hybridization and immunohistochemistry, we have studied mRNA and peptide levels in the hypothalamic paraventricular nucleus (PVN) 24 h after a single large dose of reserpine (10 mg/kg, i.p.) and 24 h after an intraventricular (i.c.v.) injection of colchicine (120 microliters/20 microliters saline). Sections of the PVN were hybridized using synthetic oligonucleotide probes complementary to mRNA for corticotropin-releasing hormone (CRH), neurotensin (NT), enkephalin (ENK), vasoactive intestinal polypeptide (VIP) and thyrotropin-releasing hormone (TRH). For immunohistochemistry rabbit antisera to CRH, NT, ENK, VIP and TRH were used. In situ hybridization showed a clear increase in CRH mRNA as compared to control rats after both treatments. Also NT and VIP mRNA could be seen in parvocellular neurons in reserpine and in colchicine-treated rats, whereas we so far have not been able to demonstrate these mRNAs in untreated rats. No changes in TRH mRNA could be detected after reserpine of colchicine. These results provide final evidence that subpopulations of parvocellular PVN neurons can synthesize not only CRH and ENK, but also NT and VIP, in agreement with earlier immunohistochemical results. With immunochemistry, after reserpine, many CRH-, but no NT- or VIP- positive neurons could be observed in the parvoecellular part of the PVN. The present results demonstrate that treatment with two drugs, the monoamine depleting drug reserpine and the mitosis inhibitor colchicine, causes increased levels of mRNA for several peptides in neurons of the PVN, located almost exclusively in its parvocellular part and being part of the hypothalamo-pituitary adrenal axis.

Animals↗

Reserpine treatment stimulates enkephalin and D2 dopamine receptor gene expression in the rat striatum.

We investigated the effect of catecholamine depletion on gene expression for preproenkephalin A (PPA) and D2 dopamine receptor (D2R) in the rat nigrostriatal complex, using quantitative Northern blot analysis. The D2R probe indifferently recognizes the two mRNA isoforms generated by alternative splicing from the same gene. Short-term and chronic reserpine treatment increase the level of PPA and D2R mRNA in the striatum in a complex manner. For short-term treatment, we injected 10 mg/kg of reserpine the first day, 5 mg/kg 24 h later and sacrificed the rats at various times after the last injection. This treatment resulted in an increase of the level of PPA mRNA by 50% and D2R mRNA up to 150%. For chronic treatment, we injected 0.5 mg/kg of reserpine for 21 days, sacrificed the rats one day after the last injection and observed an increase in PPA and D2R mRNA levels by 100%. Statistical analysis revealed that the PPA mRNA level after chronic treatment was significantly higher from the one obtained after short-term treatment while no such difference was observed for the D2R mRNA. In contrast, reserpine treatment does not modify the level of D2R mRNA in the substantia nigra suggesting that catecholamine depletion has postsynaptic but not presynaptic consequences in the rat nigrostriatal complex. These results demonstrate that reserpine acts at the gene or the mRNA level to induce dopamine supersensitivity in striatal dopaminoceptive neurons.

Animals↗

Reserpine non-selectively inhibits rat uterus contraction in vitro.

1. Reserpine produced a direct in vitro non-selective inhibitory effect on smooth muscle contraction of endometrium-free rat uterus. 2. Reserpine uptake into uterine muscle and its antagonistic effect on contraction had a similar time course. 3. Reserpine had a relaxing effect similar to that of trifluoperazine and different from that of verapamil or papaverine, and also failed to exert any inhibitory effect on 45Ca uptake rate. 4. Both reserpine and trifluoperazine but not verapamil inhibited the acetylcholine-induced contraction when present during the Ca-release from intracellular stores. 5. It is hypothesized that reserpine exerts its inhibitory action intracellularly on the activation of smooth muscle contraction by sarcoplasmic Ca2+.

Acetylcholine↗

Effect of reserpine, phenoxybenzamine and cold stress on the neuropeptide Y content of the rat peripheral nervous system.

The effect of reserpine treatment on the neuropeptide Y content of the rat adrenal gland, heart, kidney and vasculature was studied using a specific radioimmunoassay. One hour after reserpine administration (5 mg/kg) the neuropeptide Y concentration in the adrenal gland was significantly reduced and after 4 h a similar reduction was seen in the heart and kidney. After 48 h, neuropeptide Y concentrations were reduced in all tissues. The greatest reduction occurred in the cardiac septum (77%) and the least in the inferior vena cava (25%). Phenoxybenzamine (2 mg/kg) also caused a reduction in neuropeptide Y concentrations which was less marked than after reserpine, except in the adrenal gland where it was similar. Cold stress caused no change in neuropeptide Y concentrations. The neuropeptide Y depletion induced by reserpine was compared to that following 6-hydroxydopamine. In the heart and pial arteries both drugs caused a similar neuropeptide Y depletion whilst in the pineal gland and renal artery 6-hydroxydopamine had more effect than reserpine. The implications of these results on NPY storage sites are discussed.

Animals↗

Effects of chronic reserpine treatment on development of maturity of the putamen in fetal rabbits.

Developing nigrostriatal axons and their perikarya have substantial quantities of dopamine (DA) before the axons reach their postsynaptic target. In order to investigate possible developmental effects of these stores of DA, we have depleted DA chronically during critical periods in the ontogeny of the nigrostriatal system. Reserpine (0.04-0.14 mg/kg/day) was given repeatedly to maternal rabbits for various periods starting before neuroblasts of the substantia nigra first exhibit fluorescence until 2 days before term when the fetuses were sacrificed. Reserpine crossed the placenta and depleted DA in the fetal putamens. Control fetuses had widespread fluorescent axons and terminals. Counts of mature axonal boutons in electron micrographs of the putamen of reserpine-treated fetuses showed that there were 4.3 +/- 0.6 SE/100 microns2, which is less than 1/2 the control value of 10.2 +/- 0.6 SE/100 microns2 (p less than 0.001). The neuropil of the putamen of the reserpine-treated fetus was also less mature; the relative volume occupied by growth cones (40.5% +/- 5.7 SE) was twice that of controls (20.6% +/- 2.4 SE) (p less than 0.005). Although it remains to be shown that the delayed development of both pre- and postsynaptic elements of the nigrostriatal system is specifically related to the known ability of reserpine to deplete DA, the results are consistent with the hypothesis that early stores of DA may be important in developing dopaminergic systems.

Animals↗

Effect of amantadine on motility of reserpinized mice as a function of brain biogenic amines and mouse strains.

The effect of amantadine, reserpine or both on locomotor activity and whole brain content of selected biogenic amines and major metabolites was studied as a function of mouse strain. Successive administration of small dose regimens of reserpine, 0.2 mg/kg IP, did not alter motility from corresponding saline control. Administration of amantadine, 100 mg/kg, IP, prior to each of the reserpine treatments produced either stimulation of motor activity in the albino ICR and black C57BL/6 mice or caused inhibition from reserpine in the albino BALB/C and the brown CDF-1 mouse strains. This suggests a genotype strain sensitivity to the amantadine and reserpine interaction on the motor behavior of the mouse. The amantadine treatment did not alter brain dopamine concentration but increased its immediate acid metabolite, 3,4-dihydroxyphenylacetic acid, in the C57BL/6 mice as contrasted with reduction of the same in the BALB/C mouse strain. Both BALB/C and C57BL/6 mice showed changes in brain normetanephrine levels as a consequence of the pharmacologic intervention used which suggest catecholaminergic sensitivity. The only changes produced by the agents studied in brain serotonin or 5-hydroxyindoleacetic acid levels were confined to the BALB/C mouse strain. No changes occurred in brain levels of the compounds measured from corresponding controls in the CDF-1 mice. The results indicate differential sensitivity of the serotonergic and dopaminergic systems to drug-drug interaction studied which appears to be strain dependent.

Amantadine↗

Inhibitory effect of reserpine on N-2-fluorenylacetamide-induced hepatocarcinogenesis in rats.

The effect of reserpine on N-2-fluorenylacetamide (FAA)-induced hepatocarcinogenesis was examined in female ACI rats. The incidence of hepatocellular altered foci (number/cm2) in rats of group 1 given FAA (0.02% in diet) and reserpine (subcutaneous injections of 1 microgram/g body weight, once a week) simultaneously for 10 weeks, and fed a basal diet for 17 weeks was significantly smaller than that of group 3 exposed to FAA alone for 10 weeks and given the basal diet for the subsequent 17 weeks (1.51 +/- 0.58 vs. 11.46 +/- 3.13, P less than 0.001). Similarly, the incidence of the foci of group 2 given reserpine for 16 weeks after discontinuation of FAA exposure for 10 weeks and a one-week interval of basal diet, was also significantly smaller than that of group 3 (1.51 +/- 0.62 vs. 11.46 +/- 3.13, P less than 0.001). No hepatocellular foci were seen in rats of group 4 given reserpine alone for 27 weeks and group 5 (untreated controls). These results indicate that reserpine has an inhibitory effect on FAA-initiated hepatocarcinogenesis.

2-Acetylaminofluorene↗

Responses of the three-toed sloth, Bradypus tridactylus, to some commonly used pharmacologic agents. II. Chloralose and reserpine.

1. Chloralose, 50 mg/kg i.v., is a safe effective anesthetic for sloths and reduces incidence of cardiac arrhythmias. 2. However, chloralose blocks baroreflexes and may reduce the sensitivity of beta 1 cardiac receptors. 3. Reserpine, 0.70 mg/kg given i.v. in divided doses, blocks the hypertensive effect of 100 micrograms/kg of tyramine in sloths. 4. Reserpine in this dosage materially reduces arterial pressure and heart rate; these effects last at least 7 days. 5. Reserpine potentiates the hypertensive effects of epinephrine and norepinephrine materially. 6. In sloths reserpine increases cardiac irritability but does not block baroreflexes. 7. As is true with most other drugs sloths are more sensitive to chloralose and reserpine than most common laboratory animals.

Animals↗

Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756.

The effect of reserpine induced dopamine depletion on the binding of the putative dopamine-D3 receptor ligand, [(11)C]RGH-1756 was examined in the monkey brain with positron emission tomography (PET). In a previous series of experiments, we have made an attempt to selectively label D3 receptors in the monkey brain using [(11)C]RGH-1756. Despite high selectivity and affinity of RGH-1756 in vitro, [(11)C]RGH-1756 displayed only low specific binding to D3 receptors in vivo. The aim of the present study was to examine whether low specific binding of [(11)C]RGH-1756 is caused by insufficient in vivo affinity of the ligand, or by high physiological occupancy of D3 receptors by endogenous dopamine (DA). PET experiments were performed in three monkeys under baseline conditions and after administration of reserpine (0.5 mg/kg). The results of the baseline measurements corresponded well to our earlier observations with [(11)C]RGH-1756. Reserpine caused no evident change in the regional distribution of [(11)C]RGH-1756 in the monkey brain, and no conspicuous regional accumulation of activity could be observed. After reserpine treatment there was no evident increase of specific binding and binding potential (BP) of [(11)C]RGH-1756. The lack of increased [(11)C]RGH-1756 binding after reserpine treatment indicates that competition with endogenous DA is not the predominant reason for the failure of the radioligand to label D3 receptors. Therefore, the low binding of [(11)C]RGH-1756 could largely be explained by the need for very high affinity of radioligand for D3 receptors in vivo, to obtain a suitable signal for the minute densities of D3 receptors expressed in the primate brain.

Adrenergic Uptake Inhibitors↗

Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice.

There are a number of reasons for believing that nitric oxide participates in motor control in the striatum. Therefore, effects of neuronal nitric oxide synthase inhibitor 7-nitroindazole (7-NI) were studied on the reserpine model of Parkinson's disease in Swiss and C57BL/6 mice using the open-field test. Mice received reserpine (1 mg/kg administered intraperitoneally). A significant hypolocomotion was observed 24 h and 48 h after reserpine injection. The treatment with 7-nitroindazole (25 mg/kg, administered intraperitoneally, 30 min after reserpine) attenuated reserpine-induced hypolocomotion 24 h and 48 h after the treatment in Swiss mice, but not completely in C57BL/6 mice. These results suggest that nitric oxide functions as an intercellular messenger in motor circuits in the brain. Moreover, our data suggests that the comparison of such mouse strains may provide information on genetic basis for strain differences in different sensitivity to these drugs.

Adrenergic Uptake Inhibitors↗

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.

Although most commonly associated with actions at cannabinoid CB1 receptors on the extracellular surface of the plasma membrane, the endocannabinoid anandamide (AEA) is also transported into the cell, by the putative anandamide membrane transporter (AMT), and activates the vanilloid receptor 1 (TRPV1) at an intracellular site. AEA is then inactivated by fatty acid amide hydrolase (FAAH). As systemic administration of TRPV1 ligands reduces locomotor activity in normal rodents, we hypothesised that activation of TRPV1 by endocannabinoids could play a role in the control of voluntary movement and that such actions could be regulated by AMT and FAAH. Motor activity was assessed in normal, in reserpine-treated, and in reserpine-treated rats treated with L-DOPA. In normal rats, the TRPV1 agonist capsaicin (1 mg/kg) or the FAAH inhibitor URB597 (10 mg/kg) caused a significant reduction in movement in both the horizontal (locomotion) and vertical (rearing) planes (-45% and -53% respectively with capsaicin; -33% and -37% for URB597). Capsaicin-induced hypolocomotion was attenuated by the TRPV1 antagonist, capsazepine. There was no effect of capsaicin, URB597 or the AMT inhibitor OMDM-2 on motor activity in reserpine-treated rats. L-DOPA treatment of reserpine-treated rats elicited high levels of motor activity in both the horizontal and vertical planes. Horizontal activity was attenuated by capsaicin (1 mg/kg, -60%), but not by URB597 (10 mg/kg) or OMDM-2 (5 mg/kg). Vertical activity was attenuated by capsaicin (1 mg/kg, -61%) and by URB597 (10 mg/kg, -54%), but not by OMDM-2. These data suggest that activation of the TRPV1 system can suppress spontaneous locomotion in normal animals and modulates several L-DOPA-induced behaviours in reserpine-treated rats.

Adrenergic Uptake Inhibitors↗

Phosphatidylserine reverses reserpine-induced amnesia.

The effects of phosphatidylserine (PS) were studied in rats treated with reserpine (1 mg/kg) immediately after training in the passive avoidance task. In experiment I, phosphatidylserine (25 mg/kg) was administered 30 min before or immediately after training. Acute pre- or post-treatment with phosphatidylserine was effective in reversing the amnestic effect of reserpine in test trials performed 24 h and 1 week after training. Experiment II was performed to determine if the long-term pretreatment with phosphatidylserine (25 mg/kg) for 7 days is able to protect the rats against the amnestic effects of reserpine in this task. The data show that phosphatidylserine reverses the impairment induced by reserpine in trials performed 24 h and 1 week after training. These results indicate that the memory deficits associated with catecholamine depletion caused by reserpine can be attenuated by acute pre- or post-training or by long-term pretreatment with this phospholipid.

Amnesia↗